MetaCap

Bristol-Myers Squibb (BMY) vs Regeneron Pharmaceuticals (REGN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Bristol-Myers Squibb (BMY) has outperformed Regeneron Pharmaceuticals (REGN) over the past year, gaining 27.1% versus a gain of 21.8%. Over five years, REGN leads with a +43.1% price change compared with +4.0% for BMY. Bristol-Myers Squibb is the larger company by market cap ($120.19 billion vs $95.24 billion), about 1.3 times the size, while Regeneron Pharmaceuticals is growing revenue faster (+1.0% vs -0.2%).

On valuation, Bristol-Myers Squibb trades at a lower forward P/E (8.8x vs 12.8x for Regeneron Pharmaceuticals). Bristol-Myers Squibb offers the higher dividend yield (4.29% vs 0.40%). Regeneron Pharmaceuticals converts more of its revenue into profit, with a net margin of 31.4% versus 14.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BMY+27.14%REGN+21.80%
+51%+13%-24%
Nov 21, 20251 yearNov 20, 2026
BMY+1.68%REGN+41.06%
+89%+26%-37%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BMY versus REGN key metrics
MetricBMYREGN
Share price$58.80$920.69
Market cap$120.19B$95.24B
1-day change+0.79%-0.19%
YTD return+9.01%+19.28%
1-year return+27.14%+21.80%
5-year return+4.02%+43.11%
P/E ratio (TTM)13.0420.35
Forward P/E8.7812.85
EPS (TTM)$4.51$45.24
Dividend yield4.29%0.40%
Annual dividend$2.52$3.70
Revenue (latest FY)$48.19B$14.34B
Revenue growth (YoY)-0.22%+0.99%
Net income (latest FY)$7.05B$4.50B
Gross margin71.08%—
Operating margin—24.95%
Net margin14.64%31.41%
52-week high$68.64$991.73
52-week low$47.58$591.52
Distance from 52-week high-14.34%-7.16%
Analyst consensusbuybuy
Avg. price target upside+10.97%+7.64%
Average volume11.15M805.45K
Shares outstanding2.04B101.63M
Employees32,50015,410
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Regeneron Pharmaceuticals trades at a higher earnings multiple (20.4x vs 13.0x trailing P/E).
  • Bristol-Myers Squibb offers a meaningfully higher dividend yield (4.29% vs 0.40%).
  • Regeneron Pharmaceuticals is more profitable, keeping 31.4 cents of every revenue dollar as net income versus 14.6 cents for Bristol-Myers Squibb.

About Bristol-Myers Squibb

BMY stock →

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications.

Health Care · Biotechnology: Pharmaceutical Preparations · 32,500 employees

About Regeneron Pharmaceuticals

REGN stock →

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.

Health Care · Biotechnology: Pharmaceutical Preparations · 15,410 employees

BMY vs REGN FAQ

Which is bigger, Bristol-Myers Squibb or Regeneron Pharmaceuticals?

Bristol-Myers Squibb (BMY) is larger, with a market capitalization of $120.19B compared with $95.24B for Regeneron Pharmaceuticals (REGN).

Which stock has performed better over the past year, BMY or REGN?

BMY returned +27.14% over the past 12 months, compared with +21.80% for REGN (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, BMY or REGN?

BMY has the lower trailing P/E at 13.0, versus 20.4 for REGN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, Bristol-Myers Squibb or Regeneron Pharmaceuticals?

Bristol-Myers Squibb has the higher yield at 4.29%, compared with 0.40% for Regeneron Pharmaceuticals.

Are Bristol-Myers Squibb and Regeneron Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons